{"name":"Neovii Biotech","slug":"neovii-biotech","ticker":"","exchange":"","domain":"","description":"Neovii Biotech is a biotechnology company focused on developing innovative therapies in the fields of oncology and immunology. The company has a pipeline of five drugs, with two in Phase 3 trials and one in Phase 2. Neovii's lead candidate, EZ-2053, is being evaluated for its potential in treating various cancers.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5QS0lrN3k2TFloLWtSWGpYSExmR1Z1VGJZTE83cjB0eEQzUHVLRzBMQ2JfMm9BVGt2QlVYODNXVkFhTVBoTXhmUnBsQm9VYWl3b2tXb1NGNTBtMU1yR0ZPeQ?oc=5","date":"2025-08-26","type":"pipeline","source":"Oncodaily","summary":"11th Symposium of EWOG-MDS/SAA - Oncodaily","headline":"11th Symposium of EWOG-MDS/SAA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQM1hFZHBFc1docXFKWDgyS1VNVzBKdjdRMV83X1lvdFJUaWtzSmZ2WmNueXR3clc2dmhFRGU5Y0xDbjVwWjBieElUZVBXRUN1R0lQNFRoQnNlSW1hendSbWIzdHZHYmFBOXlDdkVRamZpM0RqWnZiWVpKM2Jyb3JYVThLQzN4TUJNcU0wZ3FaY1RZUUljQWdwWWZqd1A?oc=5","date":"2022-09-07","type":"pipeline","source":"newswire.com","summary":"Neovii and Fosun Pharma Enter Into an Exclusive Agreement - newswire.com","headline":"Neovii and Fosun Pharma Enter Into an Exclusive Agreement","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-05-21","type":"pipeline","source":"openPR.com","summary":"Graft-Versus-Host Disease (GVHD) Market 2019: Competitor - openPR.com","headline":"Graft-Versus-Host Disease (GVHD) Market 2019: Competitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPbFktMjdWUFJXX1NfblFqN1NLZ2lyaGJUUWFLLThyQVNYanJDSVVZY0xrdHBueTFZVFJmSlBONERwX0pLVUowSUFRc25pczRwUHVvNkJYZnkyMFJZUkxYMEp4aG9HdlpYVFVqbVJ1eXo5dlhPb2F0RkljOFV2Tl9wQlhuTEZzS2c?oc=5","date":"2018-07-05","type":"pipeline","source":"Contract Pharma","summary":"Neovii, Mundipharma Enter Agreement - Contract Pharma","headline":"Neovii, Mundipharma Enter Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNZHB0Tll1N21sM0Y1dnkzcjNJRFNyQ3E1N01VUGNxdW40NGh3eHJjeEw5UXZtZHV0TVdwM25YTF9vREcyZFNLRFZOd0NDRFRsOTEyY0wzb1VHUWF3Z0hXWk80SF9pZG1RZUYtQWtVVTFTTjA3UnBlS2ZzN3F3Nk82QmtiU3h0eEVZMDlnMzQ0VHJXbG9PMFl0a1d1QnpUMmJY?oc=5","date":"2017-09-15","type":"pipeline","source":"PR Newswire","summary":"Neovii Pharmaceuticals AG Announces New CEO - PR Newswire","headline":"Neovii Pharmaceuticals AG Announces New CEO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}